FDA Panel Endorses Synergo Combo Product For Bladder Cancer

Medical Enterprises' Synergo combination product for prevention of bladder cancer recurrence should be approved by FDA, contingent upon a one-year post-approval study to further assess its safety in the U.S. population, according to the agency's Gastroenterology and Urology Devices Panel